3 uger hos patienter med psoriasis, med et interval mellem 15 og 32 dage for alle psoriasisforsøg.
Median half-life (t1/ 2) of ustekinumab was approximately 3 weeks in patients with psoriasis, ranging from 15 to 32 days across all psoriasis studies.